Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 1334Neoplasms 1111Carcinoma, Non-Small-Cell Lung 923Prostatic Neoplasms 755Colorectal Neoplasms 653Lung Neoplasms 626Neoplasm Metastasis 476Multiple Myeloma 449Leukemia, Myeloid, Acute 441Pancreatic Neoplasms 394Ovarian Neoplasms 390Melanoma 350Carcinoma, Hepatocellular 311Brain Neoplasms 293Recurrence 289Squamous Cell Carcinoma of Head and Neck 287Glioblastoma 263Head and Neck Neoplasms 256Stomach Neoplasms 255Precursor Cell Lymphoblastic Leukemia-Lymphoma 242Carcinoma, Renal Cell 241Lymphoma 237Triple Negative Breast Neoplasms 234Endometrial Neoplasms 223Hematologic Neoplasms 220Uterine Cervical Neoplasms 217Urinary Bladder Neoplasms 213Glioma 208Lymphoma, Non-Hodgkin 206Sarcoma 204

Interventions

Letrozole 2palbociclib 1Fulvestrant 1Diet, Ketogenic 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Estrogen Receptor-positive Breast Cancer × 90 days × Clear all
NCT03962647 2026-04-30

A 2-Week Ketogenic Diet in Combination With Letrozole to Modulate PI3K Signaling in ER+ Breast Cancer

Vanderbilt-Ingram Cancer Center

Phase EARLY_PHASE1 Completed
31 enrolled
Breast

Estrogen Receptor-positive Breast Cancer

NCT03633331 2026-04-29

Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer

Alliance for Clinical Trials in Oncology

Phase 2 Completed
93 enrolled 16 charts
Breast

Estrogen Receptor-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡